Bicycle Therapeutics PLC (BCYC) Reports Q3 2023 Financial Re

Company's cash and cash equivalents stand at $572.1 million as of September 30, 2023

Related Keywords

, Research Development Rd Day On , Bicycle Therapeutics , Company Performance , Readiness Pilot , Cash And Equivalents , Ncyc , Bicycle Technology , Financial Results , Clinical Development Plan ,